Company Profile

Freeline Therapeutics Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. It is focused on improving patient lives through one-time treatments for chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient's bloodstream. Therapeutic AAV vectors consist of two main components, the capsid and the expression cassette (that contains the gene and the promoter). The Company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. The Company's pipeline includes Fabry Disease FLT190 for the treatment of Fabry disease and Gaucher Disease FLT201 for the treatment of type 1 Gaucher disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

05-04	Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of Flt201 in Adults with Gaucher Disease Type 1	CI
02-04	Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease At 22Nd Annual Worthldsymposium	CI
09/10/25	Spur Therapeutics Limited Auditor Raises 'Going Concern' Doubt	CI
09/10/25	Spur Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/10/25	Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease At ESGCT 32nd Annual Congress	CI
01/10/25	Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress	CI
06/06/25	Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson's Disease at 2025 GBA1 Meeting	CI
27/05/25	Spur Therapeutics Publishes Preclinical Proof-Of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease	CI
15/05/25	Spur Therapeutics Presents Positive New Clinical and Preclinical Data on Its Gene Therapy Programs at ASGCT 28th Annual Meeting	CI
04/02/25	Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium	CI
31/10/24	Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, Its Gene Therapy Candidate in Adrenomyeloneuropathy	CI
23/10/24	Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201	CI
08/07/24	Spur Therapeutics Completes Enrollment in Phase 1/2 Galileo-1 Trial of Flt201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial	CI

28/11/23	HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15	MT
18/10/23	Wedbush Downgrades Freeline Therapeutics to Neutral From Outperform, Cuts Price Target to $5 From $8	MT
04/10/23	Wedbush Adjusts Freeline Therapeutics Price Target to $8 From $5, Maintains Outperform Rating	MT
16/08/23	Stifel Adjusts Price Target on Freeline Therapeutics to $4 From $3, Keeps Hold Rating	MT
30/05/23	Wedbush Raises Price Target on Freeline Therapeutics to $5 From $1, Maintains Outperform Rating	MT

24/04/24	Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	AQ
20/02/24	Acquisition of Freeline by Syncona Becomes Effective	AQ
12/02/24	Freeline Shareholders Approve Acquisition by Syncona	AQ
08/12/23	Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	AQ
01/12/23	Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	PU

13/12/23	Pharma und Gesundheit: weitere Konsolidierung
12/12/23	Farma en gezondheid: consolidatie gaat door
11/12/23	Farmaceutica e salute: continua il consolidamento
11/12/23	Farmacia y salud: La consolidación continúa
11/12/23	Pharma & santé : poursuite de la consolidation

Manager	Title	Age	Since
Michael Parini CEO	Chief Executive Officer	51	16/08/2021
Markus Hörer CTO	Chief Tech/Sci/R&D Officer	-	03/04/2020
Paul Schneider DFI	Director of Finance/CFO	56	16/05/2022

Freeline Therapeutics Holdings plc Stock

Stocks

FRLN

US35655L2060

Biotechnology & Medical Research

Latest news : Freeline Therapeutics Holdings plc

Analysts' recommendations: Freeline Therapeutics Holdings plc

Press Releases: Freeline Therapeutics Holdings plc

News in other languages: Freeline Therapeutics Holdings plc

Managers and Directors: Freeline Therapeutics Holdings plc

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Chris Hollowood CHM	Chairman	52	-
Michael Parini BRD	Director/Board Member	51	16/08/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FREELINE THERAPEUTICS HOLDINGS PLC	-.--%	+0.93%	-	-	28.25M
ARGENX SE	-0.43%	-1.88%	+66.24%	+120.68%	55.63B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.52%	+88.67%	52.25B
BIONTECH SE	+1.36%	+0.36%	-14.52%	-14.67%	23.07B
INSMED INCORPORATED	-1.04%	+7.91%	+3.91%	+413.05%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	+6.78%	+14.77%	+37.54%	-1.86%	17.32B
GENMAB A/S	+0.31%	+3.02%	+29.70%	-32.72%	15.94B
EXELIXIS, INC.	+2.89%	+5.51%	+25.42%	+188.41%	13.77B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+134.32%	+282.61%	13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.21%	+11.01%	+33.13%	-	12.43B
Average	+1.16%	+4.78%	+43.92%	+130.52%	25.14B
Weighted average by Cap.	+0.87%	+5.13%	+49.88%	+122.09%